Abstral (Fentanyl) Sublingual Tablet 400 mcg – 30 pills.
Each pack contains 30 pills.
Select the number of packs below
Abstral® (Fentanyl) Sublingual Tablet 400 mcg – 30 Pills Pain is a significant and frequent consequence of cancer and one of the most feared symptoms associated with the diagnosis of cancer.1,2 Patients report that pain is associated with significant levels of physical discomfort, negative effects on their ability to engage in their usual activities, and diminished overall quality of life.1 A meta-analysis of 52 studies calculated the pooled prevalence rates for cancer pain with results indicating that pain affected 33% of patients with newly diagnosed cancer (95% confidence interval [CI], 21%–46%), 59% of those undergoing therapy (95% CI, 44%–73%), 64% of patients with advanced disease (95% CI, 58%–69%), and 53% of patients with all stages of disease (95% CI, 43%–63%).2
Among 18 studies characterizing the severity of pain experienced by patients, more than one-third described their pain as moderate or severe.2 Interviews conducted with 5,084 adults with cancer revealed that 56% of patients rated the intensity of their pain to be 5 or greater on a validated numerical rating scale (NRS) of 0 to 10 (where 0 = no pain and 10 = worst pain ever) and also reported several recurrent pain episodes in the past month.3 Notably, only 48% of adult patients with cancer-related pain reported good quality of life, whereas 51% indicated that pain interfered with their cognitive function, 69% reported disruptions in activities of daily living, 43% felt pain made them a burden on others for care, 30% experienced a level of pain that prevented them from performing self-care activities, and 52% indicated diminished work performance.3 Emotional reactions to pain included feelings of distress (67%) and an intolerable aspect of having cancer (36%), with 32% of patients indicating that they experienced pain of such severity they felt they would rather die.3
The significant negative consequences of pain among cancer patients are a treatment priority for clinicians according to national and international guidelines.1,4 The World Health Organization (WHO) established an initial treatment algorithm for cancer pain management and recommended initiating treatment with acetaminophen or a nonsteroidal anti-inflammatory agent (NSAID), progressing to weak opioids for patients requiring additional relief, and the use of strong opioids (e.g., morphine) for pain not effectively controlled by milder agents.1,4 These guidelines have since been updated to more accurately reflect the complexities of effective pain management for patients with cancer.1,5–7 These updated guidelines include dosing recommendations for different classes of pharmacological agents (NSAIDS, opioids, and co-analgesics), frequently used to treat pain in cancer patients, as well as recommendations for titration and dose rotations, escalation of dosing, management of side effects, and alternative interventions for management of cancer pain.1